| Identification | Back Directory | [Name]
Piclamilast | [CAS]
144035-83-6 | [Synonyms]
RP 73401
RPR 73401
piclamilas
Piclamilast
N-(3,5-Dichloropyrid-4-yl)-3-cyclopentyloxy-4-methoxybenzamide
3-(cyclopentyloxy)-N-(3,5-dichloro-4-pyridyl)-4-methoxybenzamide
3-(Cyclopentyloxy)-N-(3,5-dichloro-4-pyridinyl)-4-methoxybenzamide
3-(Cyclopentyloxy)-N-(3,5-dichloropyridin-4-yl)-4-methoxybenzamide
Benzamide,3-(cyclopentyloxy)-N-(3,5-dichloro-4-pyridinyl)-4-methoxy- | [Molecular Formula]
C18H18Cl2N2O3 | [MOL File]
144035-83-6.mol | [Molecular Weight]
381.25 |
| Chemical Properties | Back Directory | [Boiling point ]
447.8±45.0 °C(Predicted) | [density ]
1.370 | [storage temp. ]
2-8°C | [solubility ]
DMSO: soluble20mg/mL, clear | [form ]
powder | [pka]
10.10±0.70(Predicted) | [color ]
white to beige |
| Hazard Information | Back Directory | [Uses]
Piclamilast is a potent and selective phosphodiesterase-4 (PDE4) inhibitor. Piclamilast may offer therapeutic strategies in respiratory diseases, including asthma and chronic obstructive pulmonary disease. Piclamilast may also provide a treatment option for pre-term infants with bronchopulmonary dysplasia (BPD). | [Definition]
ChEBI: A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of 3-(cyclopentyloxy)-4-methoxybenzoic acid with the primary amino group of 3,5-dichloropyridin-4-amine. | [Biological Activity]
Piclamilast is a potent and selective cyclic AMP phosphodiesterase-4 inhibitor th at exhibits equalhigh affinity for both the PDE4 high- and low-affinity rolipram binding states (HARBS and LARBS). Recent studies shown th at piclamilast inhibits Trypanosoma brucei PDEB1 (TbrPDEB1) and TbrPDEB2.''Piclamilast is also known as N-(3,5-dichloropyrid-4-yl)-3-cyclopentyloxy-4-methoxybenzamide. Piclamilast regulates the cAMP (cyclic adenosine monophosphate) signaling pathway. It increases the retinoid-dependent transactivation and the degradation of retinoic acid receptor α (RARα). | [in vivo]
Piclamilast (RP 73401, 10 mg/kg, 30 min) alone does not affect the MST of leukemia-bearing animals. Piclamilast combined with ATRA (HY-14649) significantly more effective than ATRA alone in increasing the MST (40 days; interval 34–45 days) of leukemia-bearing animals[3]. | Animal Model: | SCID mice[3]. | | Dosage: | 10 mg/kg (combined with ATRA (HY-14649)). | | Administration: | Injection daily. | | Result: | Significantly more effective than ATRA alone in increasing the MST (40 days; interval 34–45 days) of leukemia-bearing animals. |
| [IC 50]
PDE4: 16 nM (IC50, in pig aorta); PDE4: 2 nM (IC50, in eosinophil soluble); PDE1: >100 μM (IC50); PDE2: 40 μM (IC50); PDE3: >100 μM (IC50); PDE5: 14 μM (IC50) | [storage]
Store at RT |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
|